TG Therapeutics, a company operating in the biopharmaceutical sector, has seen a notable increase in its stock value this year, largely attributed to strategic developments surrounding its drug BRIUMVI. Initially, BRIUMVI was utilized in single 600 mg infusions for treating relapsing multiple sclerosis. However, TG Therapeutics has broadened its scope by initiating new trials to assess BRIUMVI’s effectiveness in treating other conditions such as myasthenia gravis and treatment-resistant schizophrenia. This expansion strategy has resulted in a substantial 98.4% rise in the company’s stock price since the start of the year, a figure that also accounts for dividends1.
Investors who considered TG Therapeutics at the beginning of the year faced a decision heavily reliant on the success of BRIUMVI and the company’s ability to sustain profit margins. At that time, the stock was priced at US$29.81, and two potential narratives were at play. The optimistic scenario projected a fair value of US$40.5, based on the assumption that BRIUMVI would drive long-term revenue growth and profit margin expansion, supported by a streamlined cost structure and expanded market access. On the other hand, the pessimistic outlook suggested a fair value of US$11, highlighting risks such as over-reliance on BRIUMVI, potential pricing pressures, and increasing competition in the anti-CD20 market2.
Financially, TG Therapeutics reported BRIUMVI-driven revenue of US$240.3 million in the second quarter of 2026, marking a significant increase from US$141.1 million in the same quarter of the previous year. This revenue growth aligns with the optimistic narrative. However, the company’s net income declined to US$7.8 million, and the net margin contracted from 20.0% to 3.2%, indicating challenges in maintaining profitability3.
Currently, TG Therapeutics’ stock is trading at US$58.08, suggesting that the market has already factored in much of the positive news. The ongoing narrative now centers on whether the economics heavily reliant on BRIUMVI can sustain profitability amid rising research and development, manufacturing costs, and governance concerns. The critical question for investors is whether the expansion of BRIUMVI and new initiatives can offset these rising operational costs and any governance issues stemming from ongoing investigations.
As one analyst noted, “The main thing that has to go right is that the company converts the current BRIUMVI patient base, lifecycle programs, and emerging pipeline into durable, high-margin recurring earnings while managing rising operating costs and any governance overhang from the ongoing investigation.” This statement encapsulates the challenges and opportunities facing TG Therapeutics as it navigates its growth trajectory.
While some narratives suggest that the current stock price may not fully reflect the company’s potential, TG Therapeutics remains a focal point for investors interested in the healthcare sector. The company’s future hinges on its ability to effectively leverage BRIUMVI and its pipeline while managing costs and addressing any governance challenges.
For those seeking contrarian investment opportunities, the article hints at other companies trading below estimated fair values. However, it emphasizes that such opportunities require careful analysis and consideration of broader market conditions. Investors are encouraged to conduct thorough research and consider various factors before making investment decisions.
In summary, TG Therapeutics’ recent stock surge is a testament to its strategic efforts in expanding the application of BRIUMVI. However, the company faces ongoing challenges related to profitability and governance, which will be crucial in determining its long-term success. Investors must weigh these factors carefully as they consider the potential risks and rewards associated with the company’s growth strategy.
Footnotes:
- TG Therapeutics’ stock has risen by 98.4% since the start of the year, including dividends. Source.
- The optimistic scenario for TG Therapeutics projected a fair value of US$40.5, while the pessimistic view suggested US$11. Source.
- TG Therapeutics reported BRIUMVI-driven revenue of US$240.3 million in Q2 2026, up from US$141.1 million the previous year. Source.
Featured Image: Megapixl @ Stokkete
